Monoclonal gammopathy of undetermined significance screening: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
== Overview == | == Overview == | ||
There is no role of screening in patients for [[monoclonal gammopathy of undetermined significance]]. | |||
<br /> | |||
== Screening == | |||
__NOTOC__ | __NOTOC__ | ||
{{Monoclonal gammopathy of undetermined significance }} | {{Monoclonal gammopathy of undetermined significance }} | ||
There is no role of screening in patients for [[monoclonal gammopathy of undetermined significance]]<ref name="pmid20507313">{{cite journal |vauthors=Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA |title=Monoclonal gammopathy of undetermined significance: a consensus statement |journal=Br. J. Haematol. |volume=150 |issue=1 |pages=28–38 |date=July 2010 |pmid=20507313 |doi=10.1111/j.1365-2141.2010.08207.x |url=}}</ref> | There is no role of screening in patients for [[monoclonal gammopathy of undetermined significance|monoclonal gammopathy of undetermined significance.]]<ref name="pmid20507313">{{cite journal |vauthors=Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA |title=Monoclonal gammopathy of undetermined significance: a consensus statement |journal=Br. J. Haematol. |volume=150 |issue=1 |pages=28–38 |date=July 2010 |pmid=20507313 |doi=10.1111/j.1365-2141.2010.08207.x |url=}}</ref> | ||
==References== | ==References== | ||
Revision as of 13:54, 24 October 2019
Overview
There is no role of screening in patients for monoclonal gammopathy of undetermined significance.
Screening
|
Monoclonal gammopathy of undetermined significance Microchapters |
|
Differentiating Monoclonal gammopathy of undetermined significance from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Monoclonal gammopathy of undetermined significance screening On the Web |
|
American Roentgen Ray Society Images of Monoclonal gammopathy of undetermined significance screening |
|
FDA on Monoclonal gammopathy of undetermined significance screening |
|
on Monoclonal gammopathy of undetermined significance screening |
|
Monoclonal gammopathy of undetermined significance screening in the news |
|
Blogs on Monoclonal gammopathy of undetermined significance screening |
|
Directions to Hospitals Treating Monoclonal gammopathy of undetermined significance |
|
Risk calculators and risk factors for Monoclonal gammopathy of undetermined significance screening |
There is no role of screening in patients for monoclonal gammopathy of undetermined significance.[1]
References
- ↑ Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA (July 2010). "Monoclonal gammopathy of undetermined significance: a consensus statement". Br. J. Haematol. 150 (1): 28–38. doi:10.1111/j.1365-2141.2010.08207.x. PMID 20507313.